EUROBIO SCIENTIFIC FINALIZES THE ACQUISITION OF GENDX, INTERNATIONAL HLA DIAGNOSTICS SPECIALIST

EUROBIO SCIENTIFIC FINALIZES THE ACQUISITION OF GENDX,

INTERNATIONAL HLA DIAGNOSTICS SPECIALIST

•         Acceleration of strategic plan confirming its positioning as a leader in the molecular diagnostics market
•        Acquisition of a 100% proprietary products portfolio
•         New high-level R&D and bioinformatics teams
•         Products marketed in many countries on several continents
•         Strong technological and commercial complementarities
•         Finalization of a €90 million bank loan

Paris, October 3, 2022 – 5:50 pm

Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in vitro medical diagnostics and life sciences, announces the acquisition on October 3, 2022 of 100% of the capital and voting rights of the Dutch company Genome Diagnostics BV (GenDx) from its founder and its shareholders for an amount of 135 million euros (net of adjusted cash). The share purchase agreement signed on August 17, 2022 was subject to the finalization of a €90 million bank loan, which was confirmed last Friday September 30 by the Group’s bank syndicate with LCL, BNP, Credit Agricole Ile de France, BRED and CIC. The acquisition price was paid with the Group’s cash, and partially with the €90 million financing. This acquisition will allow Eurobio Scientific to complete its commercial portfolio with a portfolio of 100% proprietary products among the most efficient in the field of HLA¹ diagnostics in order to assess the compatibility between donors and recipients in the context of organ and marrow transplants. It will also strengthen its geographical footprint, mainly in Europe and the USA.

One of the world leaders in HLA typing for graft compatibility

Founded in 2005 in Utrecht, the Netherlands, GenDx specializes in the molecular diagnostics of transplants by HLA typing of organs or patients as part of the evaluation of compatibility between donors and recipients. Among others, it is one of the pioneers of typing based on genomic sequencing (SBT or Sequencing Based Typing) for which it currently offers high-resolution solutions based on the most recent NGS² technologies.

GenDx develops and markets a complete family of products which includes:
-         reagents for performing HLA typing by sequencing;
-        software for analyzing sequencing results, customized for different sequencing techniques and platforms;
-         training modules, facilitating the adoption of its solutions by its customers.

The company has more than 80 employees, mainly based in the Netherlands, including a sales force present in Benelux, Germany and the USA. In 2021, GenDx generated €17 million in revenue, for €6.9 million in EBITDA. During the first half of 2022, GenDx's revenue is estimated at €11.2 million, for €5.4 million of EBITDA³.

An acquisition with strong potential for growth and value creation

In 2021, transplantation diagnostics accounted for 23.8% of Eurobio Scientific Group's (the “Group”) non-COVID revenue, i.e. 20 million euros. The acquisition of GenDx should enable the consolidation of the Group's presence in this specialty and generate new international development synergies.

The main synergies linked to this acquisition are:
-        a strong complementarity of transplantation activities: Eurobio Scientific is currently only a distributor in France where GenDx has no direct presence;
-        R&D complementarity: GenDx supplements the Group's scientific and technical expertise with significant know-how in HLA and NGS within teams operating in a center of excellence in Utrecht;
-        GenDx's technological advance in the digitization of diagnostics, through algorithms and software developed by its bioinformatics specialists;
-        an extension of the international commercial presence by the direct presence of GenDx in the Netherlands, Germany and North America where it will supplement the local capacities of Eurobio Scientific, and by its distributors in the rest of Europe, Asia and the rest of the world.

The valuation of this transaction is in line with those of recent acquisitions involving similar assets in the field of medical diagnostics. The various synergies that were identified, will also be added to GenDx’s current value. These synergies will mainly derive from the strong complementarity in terms of R&D, the extension of the Group’s commercial presence and resulting cross-sales, and more generally the new dynamics originating from the mix of expertise : commercial for Eurobio Scientific and scientific for GenDx.

Better access to care and advances in medicine are resulting in a growing demand for transplants. However, this is hampered by the availability of organs to be transplanted. A precise and rapid diagnosis, making it possible to increase the success rate of these surgeries, promotes a better balance between supply and demand. The transplant diagnostics market is therefore growing rapidly, and the technological and commercial strength of the new entity resulting from the merger of Eurobio Scientific and GenDx, should make it a leading player.

Denis Fortier, Deputy Managing Director and co-CEO of Eurobio Scientific, Chairman of EurobioNext, declares: "This operation is transformative for Eurobio Scientific and is fully in line with the development strategy that we have been successfully pursuing for several years and which is based on a direct presence in Europe and an increase in the share of proprietary products. The strong complementarity between our two groups should make it possible to increase the advance of our Group both technologically, geographically and commercially”.

Hervé Duchesne de Lamotte, Deputy Managing Director and CFO of Eurobio Scientific, adds: "This merger, which has the support of our financial partners, will allow Eurobio Scientific to significantly increase the share of proprietary products in its turnover and therefore its profitability. The size of the financing associated with this transaction also gives Eurobio Scientific the means to steadily pursue the development of the Group”.

“We are particularly proud of this acquisition of GenDx which will further strengthen the added value of Eurobio Scientific's innovation. It is the fruit of historical relations between Denis Fortier and Wietse Mulder, two entrepreneurs who share the same vision of the development of their business. We are convinced that GenDx will play an important role in the development of Eurobio Scientific around NGS technology as well as on the two challenges of the future which are preventive medicine and smart health”, comments Arthur Vigneras, Investment Director with NextStage AM.

Wietse Mulder, CEO and co-founder of GenDx, adds “For GenDx it was important to get closer to a group led by entrepreneurs. Eurobio Scientific, through its demonstrated agility during the COVID crisis and its complementarity with our activities, quickly appeared to us as the best partner to ensure the continued development of transplantation activities, while strengthening the technological base of our new Group. On a more personal note, I am delighted to join this new group and enable the creation of a leading player in the field of molecular diagnostics in Europe ”.

Cash and bank loan financing

The acquisition was financed in part by the Group's own cash and in part by a loan from a syndicate bringing together the Group's banks, LCL, BNP, Crédit Agricole Ile de France, BRED and CIC. The loan is for a total amount of 90 million euros. It will be amortized half-yearly over a period of six years for 63 million euros, and will be repayable in fine at the end of the seventh year for 27 million euros. The interest rate will be EURIBOR⁴ plus a margin varying according to certain financial ratios and ranging between 0.9 and 1.6% for the amortized tranche, and between 1.75 and 2.45% for the in fine tranche. A portion of this loan will be used to repay the outstanding balance of the March 2020 syndicated loan, for approximately €4.5 million. During a three-year period, Eurobio Scientific may expand the loan by €40 million, in order to preserve financial resources activable for new investments or potentially new acquisitions.

List of participants in the transaction

Eurobio Scientific: Denis Fortier (Deputy Managing Director, co-CEO) and Hervé Duchesne de Lamotte (Deputy Managing Director, CFO), Jean-Michel Carle (President and CEO)
NextStage AM: Grégoire Sentilhes (Co-founder, Chairman and CEO), Arthur Vignéras (Investment Director) and Emilio Johnston (Associate)
M&A Buyside Advisor: Rothschild & Co. (Elena Coluccelli, Philippe de Montreynaud, Dimitrios Iroidis)
Legal Buyside Advisor, legal and social DD: Jones Day (Floris Pierik, Renaud Bonnet, Maarten De Boorder)
Financial and fiscal DD: Deloitte (Justin Hamers, Martijn Koedijk, Thomas Fischer)

Next financial meeting
2022 Half-year results: October 11, 2022, before market opens

1 Human Leucocyte Antigen
2 Next Generation Sequencing
3 Non audited
4 Euro InterBank Offered Rate, the average interest rate at which a number of major European banks lend funds to each other. Currently the 6-month EURIBOR is close to 0.7%.

Attachment

• 221003_PR_Eurobio Scientific_Closing_GenDx_EN